Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Bill KL, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, Barriere C, Debussche L, Lazar AJ, Prudner BC, Casadei L, Braggio D, Lopez G, Zewdu A, Bid H, Lev D, Pollock RE. Bill KL, et al. Among authors: garnett j. Clin Cancer Res. 2016 Mar 1;22(5):1150-60. doi: 10.1158/1078-0432.CCR-15-1522. Epub 2015 Oct 16. Clin Cancer Res. 2016. PMID: 26475335 Free PMC article.
AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas.
May CD, Garnett J, Ma X, Landers SM, Ingram DR, Demicco EG, Al Sannaa GA, Vu T, Han L, Zhang Y, Kivlin CM, Bolshakov S, Kalam AA, Liu J, Zhou F, Broccoli D, Wang WL, Lazar AJ, Pollock RE, Lev D, Torres KE. May CD, et al. Among authors: garnett j. BMC Cancer. 2015 Nov 14;15:901. doi: 10.1186/s12885-015-1916-3. BMC Cancer. 2015. PMID: 26573603 Free PMC article.
Correction: SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Bill KLJ, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, Barriere C, Debussche L, Lazar AJ, Prudner BC, Casadei L, Braggio D, Lopez G, Zewdu A, Bid H, Dina L, Pollock RE. Bill KLJ, et al. Among authors: garnett j. Clin Cancer Res. 2022 Jan 15;28(2):431. doi: 10.1158/1078-0432.CCR-21-4243. Clin Cancer Res. 2022. PMID: 35045964 No abstract available.
Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer.
McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin SY. McGrail DJ, et al. Among authors: garnett j. Cancer Cell. 2020 Mar 16;37(3):371-386.e12. doi: 10.1016/j.ccell.2020.01.011. Epub 2020 Feb 27. Cancer Cell. 2020. PMID: 32109374 Free PMC article.
195 results